Cullinan Therapeutics (CGEM) Cash from Financing Activities (2020 - 2026)

Cullinan Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $380000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $380000.0; the TTM figure through Mar 2026 stood at $1.5 million (down 99.45% YoY), while the FY2025 annual figure was $1.1 million, down 99.59% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $380000.0, down from $715000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $262.2 million in Q2 2024, with the low at -$32.9 million in Q4 2022.
• The 5-year median for Cash from Financing Activities is $1.3 million (2024), against an average of $18.8 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 1318.06% in 2022, then jumped 1817.64% in 2023.
• Cullinan Therapeutics' Cash from Financing Activities stood at -$32.9 million in 2022, then soared by 100.75% to $248000.0 in 2023, then jumped by 537.9% to $1.6 million in 2024, then sank by 54.8% to $715000.0 in 2025, then sank by 46.85% to $380000.0 in 2026.
• Business Quant data shows CGEM's Cash from Financing Activities at $380000.0 in Q1 2026, $715000.0 in Q4 2025, and $373000.0 in Q2 2025.